Gerard J. Criner
Elite in Chronic Obstructive Pulmonary Disease (COPD)

Dr. Gerard J. Criner

Pulmonary Medicine
Temple Faculty Practice Plan Inc
3401 N Broad St, 
Philadelphia, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Elite in Chronic Obstructive Pulmonary Disease (COPD)
Temple Faculty Practice Plan Inc
3401 N Broad St, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gerard Criner is a Pulmonary Medicine provider in Philadelphia, Pennsylvania. Dr. Criner and is rated as an Elite provider by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Bronchitis, Lung Transplant, and Embolectomy.

His clinical research consists of co-authoring 469 peer reviewed articles and participating in 36 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 350 articles and participated in 14 clinical trials in the study of Chronic Obstructive Pulmonary Disease (COPD).

Specialties
Pulmonary Medicine
Licenses
Internal Medicine in PA
Hospital Affiliations
Chester County Hospital
Temple University Hospital
Bryn Mawr Hospital
Riddle Memorial Hospital
Beebe Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AmeriHealth
  • EPO
  • HMO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independence
  • EPO
  • HMO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

TEMPLE FACULTY PRACTICE PLAN INC
3401 N Broad St, Philadelphia, PA 19140

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

36 Clinical Trials

The American Lung Association (ALA) Lung Health Cohort
The American Lung Association (ALA) Lung Health Cohort
Enrollment Status: Recruiting
Publish Date: March 26, 2025
Zephyr Valve Registry
Zephyr Valve Registry
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2025
Intervention Type: Device
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Intervention Type: Combination product, Other
Study Drug: Extracorporeal Photopheresis (ECP)
Study Phase: Phase 3
An Observational Study of Beta-Blocker Use in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Acute Myocardial Infarction
An Observational Study of Beta-Blocker Use in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Acute Myocardial Infarction
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Other
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Biological, Drug
Study Drug: Mepolizumab
Study Phase: Phase 3
A Randomized, Controlled, Open-labeled, Multi-center Clinical Trial to Evaluate the Safe and Effective Performance of the Lungpacer Diaphragm Pacing Therapy System in Patients Who Have Failed to Wean From Mechanical Ventilation.
A Randomized, Controlled, Open-labeled, Multi-center Clinical Trial to Evaluate the Safe and Effective Performance of the Lungpacer Diaphragm Pacing Therapy System in Patients Who Have Failed to Wean From Mechanical Ventilation.
Enrollment Status: Terminated
Publish Date: December 09, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Multicenter, Randomized, Sham-controlled Study to Evaluate Safety and Efficacy After Treatment with the Nuvaira™ Lung Denervation System in Patients with Chronic Obstructive Pulmonary Disease (COPD)
A Multicenter, Randomized, Sham-controlled Study to Evaluate Safety and Efficacy After Treatment with the Nuvaira™ Lung Denervation System in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2024
Intervention Type: Other, Device
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease
A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease
Enrollment Status: Completed
Publish Date: September 23, 2024
Intervention Type: Biological, Drug
Study Drugs: Otilimab, Standard of Care
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene)
Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene)
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2024
A Sham Controlled Prospective Randomized Clinical Trial of the RejuvenAir® System for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
A Sham Controlled Prospective Randomized Clinical Trial of the RejuvenAir® System for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema
Enrollment Status: Completed
Publish Date: May 31, 2024
Intervention Type: Other, Device
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
Safety and Effectiveness of the Spiration Valve System (SVS) in Air Leaks
Safety and Effectiveness of the Spiration Valve System (SVS) in Air Leaks
Enrollment Status: Terminated
Publish Date: April 04, 2024
Intervention Type: Device
Study Phase: Not Applicable
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drugs: Infliximab, Abatacept, Remdesivir, Cenicriviroc
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
Enrollment Status: Terminated
Publish Date: July 24, 2023
Intervention Type: Drug
Study Drug: Casirivimab+Imdevimab
Study Phase: Phase 3
Pulmonary Fibrosis Foundation Patient Registry
Pulmonary Fibrosis Foundation Patient Registry
Enrollment Status: Completed
Publish Date: July 07, 2023
A Clinical Evaluation of the RheOx Bronchial Rheoplasty System for the Treatment of the Symptoms of Chronic Bronchitis in Adult Patients With COPD
A Clinical Evaluation of the RheOx Bronchial Rheoplasty System for the Treatment of the Symptoms of Chronic Bronchitis in Adult Patients With COPD
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2023
Intervention Type: Device
Study Phase: Not Applicable
RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
Enrollment Status: Completed
Publish Date: April 13, 2023
Intervention Type: Drug
Study Drug: Indacaterol/Glycopyrrolate
Study Phase: Phase 3
Nintedanib Plus Usual Transplant Care Compared to Usual Transplant Care Alone After Single Lung Transplantation in Patients With Idiopathic Pulmonary Fibrosis: a Pilot Randomized Controlled Trial
Nintedanib Plus Usual Transplant Care Compared to Usual Transplant Care Alone After Single Lung Transplantation in Patients With Idiopathic Pulmonary Fibrosis: a Pilot Randomized Controlled Trial
Enrollment Status: Terminated
Publish Date: April 07, 2023
Intervention Type: Drug
Study Drug: Nintedanib
Study Phase: Phase 2
A Phase 2, Randomized, Placebo-controlled, Double-blind, Dose-ranging Study Evaluating LTI-01 (Single-chain Urokinase Plasminogen Activator, scuPA) in Patients With Infected, Non-draining Pleural Effusions
A Phase 2, Randomized, Placebo-controlled, Double-blind, Dose-ranging Study Evaluating LTI-01 (Single-chain Urokinase Plasminogen Activator, scuPA) in Patients With Infected, Non-draining Pleural Effusions
Enrollment Status: Completed
Publish Date: March 30, 2023
Intervention Type: Drug
Study Drug: LTI-01
Study Phase: Phase 2
A Prospective, Multi-Center, Randomized, Controlled, Pivotal Trial to Validate the Safety and Efficacy of the Hemolung® Respiratory Assist System for COPD Patients Experiencing an Acute Exacerbation Requiring Ventilatory Support
A Prospective, Multi-Center, Randomized, Controlled, Pivotal Trial to Validate the Safety and Efficacy of the Hemolung® Respiratory Assist System for COPD Patients Experiencing an Acute Exacerbation Requiring Ventilatory Support
Enrollment Status: Terminated
Publish Date: October 14, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
INtervention Study In overweiGHT Patients With COPD
INtervention Study In overweiGHT Patients With COPD
Enrollment Status: Completed
Publish Date: April 07, 2022
Intervention Type: Behavioral
Study Phase: Not Applicable
The CRISIS Study: A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19)
The CRISIS Study: A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19)
Enrollment Status: Completed
Publish Date: February 17, 2022
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19
A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19
Enrollment Status: Completed
Publish Date: November 12, 2021
Intervention Type: Drug
Study Phase: Phase 1
Immunotherapy of COVID-19 With B-Cell Activating CPI-006 Monoclonal Antibody
Immunotherapy of COVID-19 With B-Cell Activating CPI-006 Monoclonal Antibody
Enrollment Status: Completed
Publish Date: July 21, 2021
Intervention Type: Drug, Other
Study Drug: CPI-006 Anti-CD73 Antibody
Study Phase: Phase 1
Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing
Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing
Enrollment Status: Completed
Publish Date: May 10, 2021
Intervention Type: Device
Study Phase: Not Applicable
Beta-Blockers for the Prevention of Acute Exacerbations of COPD
Beta-Blockers for the Prevention of Acute Exacerbations of COPD
Enrollment Status: Terminated
Publish Date: January 25, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-1499 (COVI-GUARD™) in Hospitalized Patients With Moderate COVID-19
A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-1499 (COVI-GUARD™) in Hospitalized Patients With Moderate COVID-19
Enrollment Status: Withdrawn
Publish Date: January 08, 2021
Intervention Type: Drug, Other, Biological
Study Phase: Phase 1
A Randomized, Double-blind (Sponsor Unblind), Placebo-controlled, Multi-centred Phase IIa Study to Evaluate the Safety and Efficacy of 13 Weeks of Once Daily Oral Dosing of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Older Men and Post Menopausal Women With COPD and Muscle Weakness, Participating in Home Exercise
A Randomized, Double-blind (Sponsor Unblind), Placebo-controlled, Multi-centred Phase IIa Study to Evaluate the Safety and Efficacy of 13 Weeks of Once Daily Oral Dosing of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Older Men and Post Menopausal Women With COPD and Muscle Weakness, Participating in Home Exercise
Enrollment Status: Completed
Publish Date: July 15, 2020
Intervention Type: Drug
Study Phase: Phase 2
Effects of Roflumilast in Hospitalized COPD on Mortality and Re-hospitalization
Effects of Roflumilast in Hospitalized COPD on Mortality and Re-hospitalization
Enrollment Status: Completed
Publish Date: March 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2
Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2
Enrollment Status: Completed
Publish Date: November 01, 2019
Intervention Type: Device
Study Phase: Not Applicable
Lung Tissue Research Consortium
Lung Tissue Research Consortium
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Procedure
The Pennsylvania Idiopathic Pulmonary Fibrosis State-wide Research Registry
The Pennsylvania Idiopathic Pulmonary Fibrosis State-wide Research Registry
Enrollment Status: Completed
Publish Date: October 11, 2018
View 35 Less Clinical Trials

469 Total Publications

Effect of oral treatment with quercetin on inflammatory and oxidative stress markers in patients with chronic obstructive pulmonary disease.
Effect of oral treatment with quercetin on inflammatory and oxidative stress markers in patients with chronic obstructive pulmonary disease.
Journal: Pharmacological research. Natural products
Published: June 12, 2025
Similar Doctors
Nathaniel T. Marchetti
Elite in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Nathaniel T. Marchetti
Pulmonary Medicine
Elite in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Nathaniel T. Marchetti
Pulmonary Medicine

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (0.1 mi)
215-707-5030
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nathaniel Marchetti is a Pulmonary Medicine provider in Philadelphia, Pennsylvania. Dr. Marchetti and is rated as an Elite provider by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Acute Interstitial Pneumonia, Lung Transplant, and Endoscopy.

Elite in Chronic Obstructive Pulmonary Disease (COPD)
Dr. David A. Lipson
Pulmonary Medicine
Elite in Chronic Obstructive Pulmonary Disease (COPD)
Dr. David A. Lipson
Pulmonary Medicine

University Of Penn-Medical Group

3624 Market St, Fl 2, 
Philadelphia, PA 
 (4.2 mi)
215-662-7772
Languages Spoken:
English
See accepted insurances

David Lipson is a Pulmonary Medicine provider in Philadelphia, Pennsylvania. Dr. Lipson and is rated as a Distinguished provider by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Pneumonia, and Acute Respiratory Distress Syndrome (ARDS).

Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Albert J. Mamary
Pulmonary Medicine | Intensive Care Medicine | Sports Medicine
Distinguished in Chronic Obstructive Pulmonary Disease (COPD)
Dr. Albert J. Mamary
Pulmonary Medicine | Intensive Care Medicine | Sports Medicine

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (0.1 mi)
215-707-5030
Languages Spoken:
English

Albert Mamary is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Philadelphia, Pennsylvania. Dr. Mamary and is rated as a Distinguished provider by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Acute Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Lung Transplant, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Criner's expertise for a condition
ConditionClose
View All 10 Elite Conditions
View All 11 Distinguished Conditions
View All 18 Advanced Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile